Possible biomarkers for predicting lymph node metastasis of esophageal squamous cell carcinoma: a review

被引:22
作者
Li, Juan [1 ]
Qi, Zhan [2 ]
Hu, Yuan-Ping [1 ]
Wang, Yu-Xiang [1 ]
机构
[1] Hebei Med Univ, Hosp 4, Dept Radiotherapy, 12 Jian Kang Rd, Shijiazhuang, Hebei, Peoples R China
[2] Hebei Med Univ, Hosp 4, Dept Thorac Surg, Shijiazhuang, Hebei, Peoples R China
关键词
Lymph node metastasis; esophageal squamous cell carcinoma; biomarkers; proliferation; migration; invasion; epithelial-mesenchymal transition; chemosensitivity; ENDOTHELIAL GROWTH-FACTOR; KINASE INHIBITOR PROTEIN; IDENTIFIES HIGH-RISK; VEGF-C; POOR-PROGNOSIS; TNFAIP8; OVEREXPRESSION; ABERRANT METHYLATION; TUMOR PROGRESSION; DOWN-REGULATION; CANCER-CELLS;
D O I
10.1177/0300060518819606
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Esophageal cancer is the eighth most common form of cancer worldwide, and esophageal squamous cell carcinoma (ESCC) is a major type of esophageal cancer that arises from epithelial cells of the esophagus. Local lymph node metastasis (LNM) is a typical sign of failure for ESCC clinical treatments, and a link has been established between LNM and the aberrant expression of specific biomarkers. In this review, we summarize what is known about nine factors significantly associated with LNM in ESCC patients: phosphatase and tensin homolog (PTEN), mucin 1, vascular endothelial growth factor-C, tumor necrosis factor alpha-induced protein 8 (TNFAIP8), Raf-1 kinase inhibitory protein, stathmin (STMN1), metastasis-associated protein 1, caveolin-1, and interferon-induced transmembrane protein 3. The function of these nine proteins involves four major mechanisms: tumor cell proliferation, tumor cell migration and invasion, epithelium-mesenchymal transition, and chemosensitivity. The roles of PTEN, STMN1, and TNFAIP8 involve at least two of these mechanisms, and we suggest that they are possible biomarkers for predicting LNM in ESCC. However, further retrospective research into PTEN, STMN1, and TNFAIP8 is needed to test their possibilities as indicators.
引用
收藏
页码:544 / 556
页数:13
相关论文
共 81 条
[1]   Stathmin overexpression identifies high risk for lymphatic metastatic recurrence in pN0 esophageal squamous cell carcinoma patients [J].
Akhtar, Javed ;
Wang, Zhou ;
Jiang, Wen Peng ;
Bi, Ming Ming ;
Zhang, Zhi Ping .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2014, 29 (05) :944-950
[2]  
Ando T, 2007, ONCOL REP, V18, P601
[3]  
[Anonymous], 2014, SEER Stat Fact Sheets: All Cancer Sites
[4]   EPSTEIN-BARR VIRUS-INDUCED GENES - 1ST LYMPHOCYTE-SPECIFIC G-PROTEIN-COUPLED PEPTIDE RECEPTORS [J].
BIRKENBACH, M ;
JOSEFSEN, K ;
YALAMANCHILI, R ;
LENOIR, G ;
KIEFF, E .
JOURNAL OF VIROLOGY, 1993, 67 (04) :2209-2220
[5]   Pattern of relapse in surgical treated patients with thoracic esophageal squamous cell carcinoma and its possible impact on target delineation for postoperative radiotherapy [J].
Cai, Wen-Jie ;
Xin, Pei-Ling .
RADIOTHERAPY AND ONCOLOGY, 2010, 96 (01) :104-107
[6]   SIRT1 expression is associated with lymphangiogenesis, lymphovascular invasion and prognosis in pN0 esophageal squamous cell carcinoma [J].
Chen, Guan-qing ;
Tian, Hui ;
Yue, Wei-ming ;
Li, Lin ;
Li, Shu-hai ;
Qi, Lei ;
Gao, Cun ;
Si, Li-bo ;
Lu, Ming ;
Feng, Fei .
CELL AND BIOSCIENCE, 2014, 4
[7]  
Chu EC, 2004, MED SCI MONITOR, V10, pRA235
[8]   Aberrant Methylation-Mediated Silencing of lncRNA MEG3 Functions as a ceRNA in Esophageal Cancer [J].
Dong, Zhiming ;
Zhang, Aili ;
Liu, Shengnan ;
Lu, Fan ;
Guo, Yanli ;
Zhang, Guoqiang ;
Xu, Fenglou ;
Shi, Yabin ;
Shen, Supeng ;
Liang, Jia ;
Guo, Wei .
MOLECULAR CANCER RESEARCH, 2017, 15 (07) :800-810
[9]   Human caveolin-1 and caveolin-2 are closely linked genes colocalized with WI-5336 in a region of 7q31 frequently deleted in tumors [J].
Fra, AM ;
Mastroianni, N ;
Mancini, M ;
Pasqualetto, E ;
Sitia, R .
GENOMICS, 1999, 56 (03) :355-356
[10]   Prognostic Value of Raf Kinase Inhibitor Protein in Esophageal Squamous Cell Carcinoma [J].
Gao, Chengcheng ;
Pang, Liqun ;
Ren, Chengcheng ;
Ma, Tianheng .
PATHOLOGY & ONCOLOGY RESEARCH, 2012, 18 (02) :471-477